Investor Presentation

May 1 2021

Forward Looking Statements

Sirona Biochem cautions you that statements included in this presentation that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Investment Highlights

sirona biochem



Investment Highlights

- Technology developed in France, based on 20 years of research by award winning CSO
- Out-licensed diabetes drug TFC-039 (SGLT2 inhibitor) to Chinese pharmaceutical giant Wanbang/Fosun for commercialization in the Chinese market
- In several studies by external partners, Sirona's TFC-1067 demonstrated superiority to the previous "gold standard" hydroquinone for the treatment of dyschromia (hyperpigmentation or "dark spots" of the skin)
- 2021 launch of **first commercial product** containing TFC-1067 by licensing partner Rodan + Fields (fastest growing beauty and personal care brand in the US)
- Signed commercial-scale manufacturing agreement in China for TFC-1067
- Oct 2019, signed binding term sheet with cosmetic distributor Tinyi Trading Co. for distribution rights of TFC-1067 in Asia
- Ongoing lead determination for anti-wrinkle therapy with a novel mechanism of action with plans to enter clinical trial 2021
- Launched an anti-viral program in April 2020

Sirona Biochem is a cosmetic ingredient and drug discovery firm with a proprietary platform technology. Through its wholly-owned French subsidiary TFChem, the Company specialises in stabilising carbohydrate molecules with the goal of improving efficacy and safety. Sirona Biochem is focusing on attractive indications such as the treatment of diabetes, which is predicted to be the 7th leading cause of death by 2030.

Fundamental Data*

TSX-V	SBM
Shares Outstanding	229,893,966
Shares Fully Diluted	266,066,686
Share Price (CAD)	$0.38
Market Cap	87,360,000
Year High	$0.56
Year Low	$0.19

*May 3, 2021

sirona biochem

Technology

sirona biochem

- TFChem, a wholly-owned subsidiary of Sirona Biochem, has developed a technology that creates safer, more effective pharmaceutical and cosmetic ingredients

- The technology is typically applied to known, commercialized compounds in order to improve them

This significantly reduces the standard risk associated with R&D companies



TFChem specializes in the stabilization of carbohydrate molecules through unique, proprietary, chemistry

Carbohydrate compounds have immense commercial potential.

- They are involved in many of our body's biological processes and are also used for development of active ingredients in pharmaceuticals and cosmetics

Examples of successful carbohydrate-based drugs are:

- Anti-viral medications such as **Tamiflu,** used for the treatment of Influenza A
    - Tamiflu: sales passed $2.9 Billion USD during H1N1
- Blood thinners, such as: **Arixtra** and **Lovenox**, for the treatment of blood clots
    - Lovenox: sales of $1.73 Billion USD (2018)

sirona biochem

The challenges with carbohydrates are:

- Carbohydrates have complex syntheses requiring expert chemists
- Carbohydrates are unstable, causing lower efficacy or toxic by-products
- Carbohydrates have poor pharmacological properties

Sirona's proprietary chemistry increases the potential and reduces the drawbacks of carbohydrate molecules

sirona biochem

- Sirona’s Fluorination Chemistry Technology is the solution to unstable carbohydrate molecules.
- The chemistry strengthens the bonds of a carbohydrate molecule by strategically placing fluorine atoms.



Carbohydrate molecules are unstable by nature

Sirona’s technology stabilizes carbohydrate molecules

Business Model

- Sirona's strategy is to license or sell patented compounds to leading global companies in return for up-front fees, milestone fees and ongoing royalty payments

Product, Pipeline & Partners

sirona biochem

Pipeline

Cosmetic Products

Therapeutic Area	Compound	Status
Skincare – Dark spot corrector (Rx & OTC)	TFC-1067 & family of skin lighteners	• Completed 2nd successful clinical study • Rodan + Fields licensed 2019; first product launched 2021 • In discussion with potential partners for global rights
Cell Preservation & Repair (incl Keloid and scar therapy)	Glycoprotein library	• In vitro testing for lead determination
Skincare – Anti-Aging / Anti-wrinkle	LIP-01 (library)	• In preparation for scale-up of lead compound and safety studies

Pharmaceutical Products

Therapeutic Area	Compound	Status
Diabetes	TFC-039	• Phase I clinical trials with Wanbang/Fosun (China) • In discussion for expansion into new markets
Anti-viral	TBD	• Chemistry / In vitro preparation

TFC-1067 Clinical Study

(performed by Dr. Zoe Draelos of Dermatology Consulting Services, USA)

Sirona's TFC-1067 demonstrates superiority to the gold standard, hydroquinone, for the treatment of dyschromia (hyperpigmentation or "dark spots" of the skin)

- 12-week double blinded study with 48 participants
- TFC-1067 successfully achieved the endpoint of lightening dyschromic areas on the skin
- Areas of hyperpigmentation were significantly lightened and blended into surrounding skin, while preserving overall tone
- No clinical safety issues during the trial
- Provides strong evidence that TFC-1067 is a **safe and superior replacement to hydroquinone** for the treatment of facial hyperpigmentation

TFC-1067 2nd Clinical Study

(performed by Dermscan - a division of Eurofins)

Testing higher dose and improved formulation

Results of the trial included:

- A significant decrease in spot intensity
- A significant decrease in spot size
- A significant decrease in dark spots versus surrounding skin tone

Optimal results were obtained with the higher concentration and improved formulation:

- 100% of participants agreed their complexion was illuminated
- 100% of participants agreed their complexion was brighter
- 100% of participants agreed their skin was more even in tone
- 100% of participants agreed the product blurred imperfections
- 100% of participants agreed the product prevented new dark spots from occurring
- 100% of participants agreed the spot size and mark was reduced
- 100% of participants agreed the intensity of dark spots was reduced
- 100% of participants would purchase the product

Rodan + Fields Agreement (2019)

- In September 2019, Sirona signed a license agreement with industry leader Rodan + Fields (R+F) for the non-exclusive use of skin lightening compound TFC-1067
- “As a company committed to innovation, Rodan + Fields continually seeks out novel and ground-breaking technologies. We’re excited to partner with Sirona to commercialize this highly novel new molecule in an up-and-coming product release and deliver the well-validated benefits to our consumer base”, said Dr. Simon Craw, Senior Director of R&D *Read more here*
- R+F is a leader in their field. In 2017 the company was named the #1 Skincare Brand in North America and is the fastest growing beauty and personal care brand in the US
- First product containing TFC-1067 launched in March 2021. Many positive customer reviews following the first weeks of use

Wanbang Biopharmaceuticals Agreement (2014)

- In January 2014, Sirona signed a license agreement with Wanbang Biopharmaceuticals (Wanbang), a subsidiary of Fosun Pharmaceutical Group, which is listed on the Hong Kong stock exchange
- The license allows Wanbang to develop and commercialize Sirona's anti-diabetic SGLT2 inhibitor, TFC-039, exclusively in the People's Republic of China (PRC)
- In return for the license, Wanbang provides upfront and milestone payments of up to US$9.5M in addition to royalty payments for product sales in the PRC
- To date, Sirona has received $1.5 M in milestone payments
- TFC-039 is currently in multiple Phase I clinical trials and expected to complete in the first half of 2021
- **China diabetes market reached a value of US$ 3.8 Billion in 2019, growing at a CAGR of around 11% during 2014-2019** (https://www.imarcgroup.com/china-diabetes-market)

About Us

sirona biochem

Locations

Sirona Biochem (Parent Company)

Vancouver, BC, Canada

TFChem (Wholly Owned Subsidiary)

Val de Reuil, France

- Sirona Biochem was founded in 2009
- TFChem was acquired in 2011

Management

Howard J. Verrico, MD
Founder, Sirona Biochem
CEO and Chairman of the Board

Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a member of the College of Physicians and Surgeons of British Columbia since July 1986. Dr Verrico is currently a practicing emergency room physician. In addition, Dr. Verrico has extensive experience as a venture capitalist in the junior capital markets.



Geraldine Deliencourt-Godefroy, PhD
Founder, TFChem
Chief Scientific Officer

Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of French-based biotechnology company TFChem. Since the acquisition of TFChem by Sirona Biochem in March 2011, Dr. Deliencourt-Godefroy has assumed the role of Chief Scientific Officer. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. Previous to founding TFChem, Dr. Deliencourt-Godefroy was a scientific leader at INSA (National Institute of Applied Sciences) in Rouen, France, where she developed a new technology on stabilized carbohydrates. Previous roles also include a post-doctoral position at the University College London and doctoral research at the Research Institute of Fine Organic Chemistry in Rouen, France. Dr. Deliencourt-Godefroy received a PhD and Masters in Organic Chemistry as well as her business degree from the University of France. She is the author of several publications and patents and is also the recipient of the acclaimed Francinov Research and Innovation Medal, French Ministry of Research Award and the French Senate Award.

Management

Christopher Hopton, CPA, CGA
Chief Financial Officer

Christopher Hopton, Sirona Biochem's Chief Financial Officer, brings 28 years of expertise in financial management and operations. His extensive experience covers areas of financial planning, accounting policy and business process improvement. As a business investment and finance consultant, Mr. Hopton has worked with several public and privately-held companies. Most recently, Mr. Hopton was the Chief Financial Officer of Central Resources Corp., a junior mineral exploration company. Formerly, he held the position of Division Controller at Canadian Airlines where he was responsible for an annual operating budget of $200M. Mr. Hopton was also involved in the restructuring of 360 Networks, a network communications company, which led to a buyout by Bell Canada. Mr. Hopton earned his Bachelor of Business Administration from Simon Fraser University in British Columbia, Canada and received his professional designation as a Certified General Accountant.

Michelle Seltenrich, MBA, BSc
VP, Operations

Michelle Seltenrich brings 20 years of expertise in publicly traded biotech companies. Her experience ranges from both academic and industry R&D lab management to corporate mergers and acquisitions. Ms. Seltenrich was previously the Manager of Business Development at Forbes MediTech and was responsible for international business development, in-licensing and M&A. She co-led the team in the successful acquisition of a U.S. based biotech company. Ms. Seltenrich holds a BSc from the University of British Columbia and an MBA in Technology Management from Simon Fraser University.

Milestones

sirona biochem

Milestones achieved in the last 12 months:

- ✓ Successfully completed a clinical trial for an increased dose of TFC-1067 (.4%)
- ✓ Established large-scale manufacturing of TFC-1067 at a major manufacturer
- ✓ Published an article in a reputable industry journal
- ✓ Hired additional PhD staff for the scientific team at TFChem
- ✓ Shipped first batch of TFC-1067 to Rodan + Fields for product commercialization

Sirona anticipates achieving the following milestones

- **within the next 3 months:**
  - Finalize due diligence and agree on terms with new organization in China
  - Complete an additional licensing agreement for the SGLT2 inhibitor in new markets
  - Secure non-dilutive funding through anticipated collaborations
  - Finalize Tinyi agreement
  - Complete Phase I clinical trial in China for the SGLT2 Inhibitor and advance to Phase II

- **within the next 6 months:**
  - Scale-up batch of lead anti-aging compound
  - Complete safety studies for anti-aging compound in preparation for clinical study

- **within the next 12 months:**
  - Enter clinical trial for anti-wrinkle compound
  - Develop new anti-viral compounds and advance them into preclinical studies

www.sironabiochem.com

For more information: info@sironabiochem.com

TSX-V : SBM

Frankfurt : ZSB

US-OTC : SRBCF